Some have received research funds from industry associations, while some have served as industry consultants or advisers. EHN says the stakes are high in the controversy because it involves the European Union's strategy to regulate hormone-altering chemicals - the first attempt in the world to do so. The new rules would have sweeping, global ramifications because all companies that sell a variety of products in Europe would have to comply.